Assessment of one-year overall survival among stage III breast cancer patients
Penulis/Author
Dr. dr. Darwito, S.H, Sp.B. Subsp. Onk (K). (1); Prof. Dr. Ika Puspita Sari, S.Si., M.Si., Apt. (2); Singgih Wijayana, S.E., M.Si., Ph.D. (3); dr. Nur Azid Mahardinata (4); dr. Sumadi Lukman Anwar, M.Sc., Ph.D., Sp.B(K)Onk (5); apt. Firda Ridhayani, M.Clin.Pharm (6)
Tanggal/Date
25 2025
Kata Kunci/Keyword
Abstrak/Abstract
Background: Breast cancer is a complex disease that brings about serious health issues for women around the world and is the trigger of death for 685,000 people. The results of a comprehensive diagnosis, combined with the individual's general state, establish the appropriate therapeutic care for breast cancer patients. These management disparities have an impact on clinical outcomes, which may influence patient survival. Academic Hospital Universitas Gadjah Mada is one of Yogyakarta's cancer treatment facilities that relatively new and requires evaluation while in operation. This evaluation process is essential as a strategy to boost the therapy's effectiveness in the future year.
Objective: This formed a framework for Academic Hospital Universitas Gadjah Mada's research on assessing survival rate, especially one-year overall survival, among stage III breast cancer patients with different characteristics.
Methods: An observational study was conducted comprising a retrospective cross-sectional study of 23 breast cancer patients who were first diagnosed with stage III at Academic Hospital Universitas Gadjah Mada between April and October 2022. Data collected retrospectively from the electronic medical record followed a consecutive sampling technique. The survival time of the participants is defined as the number of months from initial diagnosis to their last status (alive, died, and loss of follow-up). One-year overall survival was projected using the Kaplan-Meier curve and presented as a percentage with a 95% confidence interval.
Results: Of the 23 patients with stage III breast cancer, all were women, and the mean age was 57.39 ± 10.417 years. The one-year overall survival for stage III breast cancer was 78.3%. In addition, metastases conditions were associated with worse one-year overall survival compared to patients without metastases (40.0% vs 88.9%, p=0.028).
Conclussion: We conclude that the survival rate of breast cancer patients in Academic Hospital Universitas Gadjah Mada remains lower than in another recent study from Indonesia. This, indicates the requirement of treatment strategies evaluation and optimization.
